Thursday, June 05, 2014 2:36:59 PM
Rigel has signed partnerships with numerous leading pharmaceutical companies including, AstraZeneca, Daiichi Sankyo, Pfizer, Merck, Johnson & Johnson, and Novartis. During our collaborations with many of these organizations, they added new programs or extended their relationship with Rigel beyond the scope of the initial agreements. These partnership programs are in addition to Rigel's own proprietary research and product development programs.
Current partnership summary:
DEVELOPMENT
PARTNER MECHANISM INDICATION YEAR
AstraZenenca IL13/IL4 inhibition Chronic Asthma 2012
BerGenBio Axl kinase inhibition Oncology 2011
Daiichi Sankyo Ubiquitin ligase target Oncology 2002
All information from company website.
Recent RIGL News
- Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update • PR Newswire (US) • 04/30/2024 12:05:00 PM
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/10/2024 08:30:00 PM
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma • PR Newswire (US) • 04/04/2024 12:05:00 PM
- Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer • PR Newswire (US) • 03/12/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:10:40 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:06:00 PM
- Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 03/05/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:16:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:15:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:15:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 12:14:43 AM
- Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update • PR Newswire (US) • 02/27/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 01:00:39 PM
- Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO® • PR Newswire (US) • 02/22/2024 12:50:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:30:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:18:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:18:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:18:16 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/02/2024 02:56:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 02:17:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 02:17:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 02:17:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 02:16:50 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 06:48:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:13 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM